Focused on advancing a portfolio of novel radiotherapeutics and diagnostics
Alpha-9 Theranostics is a clinical-stage company developing a portfolio of radiolabeled imaging and therapeutic molecules for solid and hematologic malignancies. These differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of using targeted radiation to improve the lives of patients affected by cancers.
